

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal

ABT-874 for the treatment of moderate to severe chronic plaque psoriasis

Consultee and commentator comment form

Please use this form for submitting your comments on the draft remit, draft scope and provisional matrix of consultees and commentators. It is important that you complete and return this form even if you have no comments otherwise we may chase you for a response.

Enter the name of your organisation here: British Association of Dermatologists

Comments on the draft remit and draft scope

The draft remit is the brief for a proposed appraisal, given to the Institute by the Department of Health. Appendix B contains the draft remit. The draft scope, developed from the draft remit outlines the question that the proposed appraisal would answer.

Please submit your comments on the draft remit and draft scope using the table below. **Please take note of any questions that have been highlighted in the draft scope itself** (usually found at the end of the document).

If you have been asked to comment on documents for more than one proposed appraisal, please use a separate comment form for each topic, even if the issues are similar.

If you do not have any comments to make on the draft remit and draft scope, please state this in the box below.

Comment 1: the draft remit

Section	Notes	Your comments
Appropriateness	<i>It is important that appropriate topics are referred to NICE to ensure that NICE guidance is relevant, timely and addresses priority issues, which will help improve the health of the population. Would it be appropriate to refer this topic to NICE for appraisal?</i>	YES but see comment re timing

Section	Notes	Your comments
Wording	<i>Does the wording of the remit reflect the issue(s) of clinical and cost effectiveness about this technology or technologies that NICE should consider? If not, please suggest alternative wording.</i>	YES
Timing Issues	<i>What is the relative urgency of this proposed appraisal to the NHS? Is the suggested timing for submission of evidence (see cover letter) appropriate?</i>	We feel the timing of this appraisal is premature as this drug (not yet named) is still at the stage of phase II studies. Although results so far look very promising, there is as yet no clinical experience
Any additional comments on the draft remit NO		

Comment 2: the draft scope

Section	Notes	Your comments
Background information	<i>Consider the accuracy and completeness of this information.</i>	Narrow band UVB (TLO1) phototherapy should be included in the paragraph re treatments as an alternative to PUVA
The technology/ intervention	<i>Is the description of the technology or technologies accurate?</i>	YES
Population	<i>Is the population defined appropriately? Are there groups within this population that should be considered separately?</i>	YES
Comparators	<i>Is this (are these) the standard treatment(s) currently used in the NHS with which the technology should be compared? Can this (one of these) be described as 'best alternative care'?</i>	TLO1 phototherapy should be included Ustekinumab is the only listed comparator not currently used routinely in clinical practice
Outcomes	<i>Will these outcome measures capture the most important health related benefits (and harms) of the technology?</i>	YES
Economic analysis	<i>Comments on aspects such as the appropriate time horizon.</i>	No comment

Section	Notes	Your comments
Equality	<p><i>Suggestions for factors which may help promote equality and eliminate unlawful discrimination.</i></p> <p><i>These may include issues with the intended use of the technology (including factors relating to assessment, delivery and follow up) amongst e.g. people of different race, disability, religion and sexual orientation.</i></p>	No issues
Other considerations	<p><i>Suggestions for additional issues to be covered by the proposed appraisal are welcome.</i></p>	None
Questions for consultation	<p><i>Please answer any of the questions for consultation if not covered in the above sections. If appropriate, please include comments on the proposed process this appraisal will follow (please note any changes made to the process are likely to result in changes to the planned time lines).</i></p>	<p>Subgroup suggested is appropriate</p> <p>STA appropriate</p> <p>Could form part of biologics in psoriasis MTA in the future</p>
<p>Any additional comments on the draft scope</p> <p>None</p>		

Comment 3: provisional matrix of consultees and commentators

The provisional matrix of consultees and commentators (Appendix C) is a list of organisations that we have identified as being appropriate to participate in this proposed appraisal. If you have any comments on this list, please submit them in the box below.

As NICE is committed to promoting equality and eliminating unlawful discrimination we are keen to know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

If you do not have any comments to make on the provisional matrix of consultees and commentators, please cross this box:

Comments on the provisional matrix of consultees and commentators

Comment 4: regulatory issues (for manufacturers to complete)

Section	Notes	Your comments
Remit	<i>Does the wording of the remit reflect the current or proposed marketing authorisation? If not, please suggest alternative wording.</i>	
Current or proposed marketing authorisation	<i>What are the current indications for the technology?</i>	
	<i>What are the planned indications for the technology?</i>	
	FOR EACH PLANNED INDICATION:	
	<i>What is the target date (mm/yyyy) for regulatory submission?</i>	
	<i>Which regulatory process are you following?</i>	
	<i>What is the anticipated date (mm/yyyy) of CHMP positive opinion (if applicable) and regulatory approval?</i>	
	<i>Please indicate whether the information you provide concerning the proposed marketing authorisation is in the public domain and if not when it can be released. All commercial in confidence information must be highlighted and underlined.</i>	

Please return this form, preferably by e-mail, to scopingta@nice.org.uk by **Friday 2nd January 2009**

Where email is not possible, please copy this completed form onto a CD-ROM and send to: Jenniffer Alty, Project Manager, NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD to arrive on or before the deadline. Further contact details are (☎ 0161 870 3155, fax 0207 061 9848).